Cadila Healthcare, a Rs.9,400 crore plus pharma major, has suffered setback during the second quarter ended September 2016. Its consolidated net profit declined by 28.9 per cent to Rs.338 crore from Rs.475 crore in the corresponding period of last year. Its net sales moved up marginally by 3.3 per cent to Rs.2,387 crore from Rs.2,311 crore. EBDITA declined by 14.4 per cent to Rs.540 crore from Rs.631 crore.
After the announcement of financial results, Cadila scrip declined sharply by Rs.29.20 to Rs.378.50 in the morning session as against its previous day's close of Rs.407.70. The scrip touched to its yearly highest level at Rs.437 on November 5, 2015.
for the first half ended September 2016, Cadila's consolidated net sales remained flat at Rs.4,649 crore as compared to Rs.4,621 crore, a marginal growth of 0.6 per cent. Its net profit declined by 25.8 per cent to Rs.694 crore from Rs.935 crore. With lower net profit, EPS declined to Rs.6.78 as compared to Rs.9.14 in the last period. EBDITA moved down by 11.8 per cent to Rs.1,087 crore from Rs.1,233 crore.